Abstract
Microbial fermentation can rapidly provide potent compounds that can be easily screened for biological activity, and the active components can be isolated. Its success in drug discovery has inspired extensive efforts to modulate and control the products. In this Article, we document a ‘synthetic fermentation’ of bioactive, unnatural peptides ‘grown’ from small building blocks in water using amide-forming ligations. No organisms, enzymes or reagents are needed. The sequences, structures and compositions of the products can be modulated by adjusting the building blocks and conditions. No specialized knowledge of organic chemistry or handling of toxic material is required to produce complex organic molecules. The ‘fermentations’ can be conducted in arrays and screened for biological activity without isolation or workup. As a proof-of-concept, about 6,000 unnatural peptides were produced from just 23 building blocks, from which a hepatitis C virus NS3/4A protease inhibitor with a half-maximum inhibitory concentration of 1.0 μM was identified and characterized.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Change history
07 October 2014
In the HTML version of this Article originally published, a production error led to the 'Competing financial interests' statement incorrectly reading that the authors had no competing financial interests. The statement should have read: "ETH Zürich has filed a patent application on technology related to the processes described in this article. Both authors are listed as inventors on the patent application." This is correct in the PDF and print versions, and has now been amended in the HTML version.
References
Fischbach, M. A. & Walsh, C. T. Assembly-line enzymology for polyketide and nonribosomal peptide antibiotics: logic, machinery, and mechanisms. Chem. Rev. 106, 3468–3496 (2006).
Marahiel, M. A., Stachelhaus, T. & Mootz, H. D. Modular peptide synthetases involved in nonribosomal peptide synthesis. Chem. Rev. 97, 2651–2674 (1997).
Roberts, A. A., Ryan, K. S., Moore, B. S. & Gulder, T. A. M. Total (bio)synthesis: strategies of nature and of chemists. Top. Curr. Chem. 297, 149–203 (2010).
van Wageningen, A. M. A. et al. Sequencing and analysis of genes involved in the biosynthesis of a vancomycin group antibiotic. Chem. Biol. 5, 155–162 (1998).
Weber, G., Schorgendorfer, K., Schneiderscherzer, E. & Leitner, E. The peptide synthetase catalyzing cyclosporine production in Tolypocladium niveum is encoded by a giant 45.8-kilobase open reading frame. Curr. Genet. 26, 120–125 (1994).
Duitman, E. H. et al. The mycosubtilin synthetase of Bacillus subtilis ATCC6633: a multifunctional hybrid between a peptide synthetase, an amino transferase, and a fatty acid synthase. Proc. Natl Acad. Sci. USA 96, 13294–13299 (1999).
Cane, D. E., Walsh, C. T. & Khosla, C. Biochemistry—harnessing the biosynthetic code: combinations, permutations, and mutations. Science 282, 63–68 (1998).
Wilkinson, B. & Micklefield, J. Mining and engineering natural-product biosynthetic pathways. Nature Chem. Biol. 3, 379–386 (2007).
Weist, S. & Sussmuth, R. D. Mutational biosynthesis—a tool for the generation of structural diversity in the biosynthesis of antibiotics. Appl. Microbiol. Biotechnol. 68, 141–150 (2005).
von Dohren, H., Keller, U., Vater, J. & Zocher, R. Multifunctional peptide synthetases. Chem. Rev. 97, 2675–2706 (1997).
Sattely, E. S., Fischbach, M. A. & Walsh, C. T. Total biosynthesis: in vitro reconstitution of polyketide and nonribosomal peptide pathways. Nat. Prod. Rep. 25, 757–793 (2008).
Aquino, C. et al. A biomimetic polyketide-inspired approach to small-molecule ligand discovery. Nature Chem. 4, 99–104 (2012).
Woerly, E. M., Roy, J. & Burke M. D . Synthesis of most polyene natural product motifs using just 12 building blocks and one coupling reaction. Nature Chem. 6, 484–491 (2014).
Carrillo, N., Davalos, E. A., Russak, J. A. & Bode, J. W. Iterative, aqueous synthesis of β3-oligopeptides without coupling reagents. J. Am. Chem. Soc. 128, 1452–1453 (2006).
Yu, S. Y., Ishida, H., Juarez-Garcia, M. E. & Bode, J. W. Unified synthesis of enantiopure β2h, β3h and β2,3-amino acids. Chem. Sci. 1, 637–641 (2010).
Gerfaud, T., Chiang, Y. L., Kreituss, I., Russak, J. A. & Bode, J. W. Enantioselective, chromatography-free synthesis of β3-amino acids with natural and unnatural side chains. Org. Process Res. Dev. 16, 687–696 (2012).
Njoroge, F. G., Chen, K. X., Shih, N. Y. & Piwinski, J. J. Challenges in modern drug discovery: a case study of boceprevir, an HCV protease inhibitor for the treatment of hepatitis C virus infection. Acc. Chem. Res. 41, 50–59 (2008).
Kwong, A. D., Kauffman, R. S., Hurter, P. & Mueller, P. Discovery and development of telaprevir: an NS3-4A protease inhibitor for treating genotype 1 chronic hepatitis C virus. Nature Biotechnol. 29, 993–1003 (2011).
Venkatraman, S. et al. Discovery of (1R,5S)-N-[3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl]-3-[2(S)-[[[(1,1-dimethylethyl)amino]carbonyl]amino]-3,3-dimethyl-1-oxobutyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexan-2(S)-carboxamide (SCH 503034), a selective, potent, orally bioavailable hepatitis C virus NS3 protease inhibitor: a potential therapeutic agent for the treatment of hepatitis C infection. J. Med. Chem. 49, 6074–6086 (2006).
Nett, M., Ikeda, H. & Moore, B. S. Genomic basis for natural product biosynthetic diversity in the actinomycetes. Nat. Prod. Rep. 26, 1362–1384 (2009).
Handelsman, J., Rondon, M. R., Brady, S. F., Clardy, J. & Goodman, R. M. Molecular biological access to the chemistry of unknown soil microbes: a new frontier for natural products. Chem. Biol. 5, R245–R249 (1998).
Wenzel, S. C. et al. Heterologous expression of a myxobacterial natural products assembly line in pseudomonads via red/ET recombineering. Chem. Biol. 12, 349–356 (2005).
Demain, A. L. & Adrio, J. L. Contributions of microorganisms to industrial biology. Mol. Biotechnol. 38, 41–55 (2008).
Schwarzer, D., Finking, R. & Marahiel, M. A. Nonribosomal peptides: from genes to products. Nat. Prod. Rep. 20, 275–287 (2003).
Keasling, J. D. Manufacturing molecules through metabolic engineering. Science 330, 1355–1358 (2010).
Walsh, C. T. Combinatorial biosynthesis of antibiotics: challenges and opportunities. ChemBioChem 3, 125–134 (2002).
Sieber, S. A. & Marahiel, M. A. Molecular mechanisms underlying nonribosomal peptide synthesis: approaches to new antibiotics. Chem. Rev. 105, 715–738 (2005).
Linne, U. & Marahiel, M. A. Control of directionality in nonribosomal peptide synthesis: role of the condensation domain in preventing misinitiation and timing of epimerization. Biochemistry 39, 10439–10447 (2000).
Yeh, E., Kohli, R. M., Bruner, S. D. & Walsh, C. T. Type II thioesterase restores activity of a NRPS module stalled with an aminoacyl-S-enzyme that cannot be elongated. ChemBioChem 5, 1290–1293 (2004).
Uguru, G. C. et al. Active-site modifications of adenylation domains lead to hydrolysis of upstream nonribosomal peptidyl thioester intermediates. J. Am. Chem. Soc. 126, 5032–5033 (2004).
Smith, G. P. & Petrenko, V. A. Phage display. Chem. Rev. 97, 391–410 (1997).
Roberts, R. W. & Szostak, J. W. RNA–peptide fusions for the in vitro selection of peptides and proteins. Proc. Natl Acad. Sci. USA 94, 12297–12302 (1997).
Josephson, K., Hartman, M. C. T. & Szostak, J. W. Ribosomal synthesis of unnatural peptides. J. Am. Chem. Soc. 127, 11727–11735 (2005).
Terasaka, N. & Suga, H. Flexizymes-facilitated genetic code reprogramming leading to the discovery of drug-like peptides. Chem. Lett. 43, 11–19 (2014).
Mannocci, L., Leimbacher, M., Wichert, M., Scheuermann, J. & Neri, D. 20 years of DNA-encoded chemical libraries. Chem. Commun. 47, 12747–12753 (2011).
Lam, K. S., Lebl, M. & Krchnak, V. The ‘one-bead-one-compound’ combinatorial library method. Chem. Rev. 97, 411–448 (1997).
Ripka, W. C., Barker, G. & Krakover, J. High-throughput purification of compound libraries. Drug Discov. Today 6, 471–477 (2001).
Cooper, A. J., Ginos, J. Z. & Meister, A. Synthesis and properties of the α-keto acids. Chem. Rev. 83, 321–358 (1983).
Dumas, A. M. & Bode, J. W. Synthesis of acyltrifluoroborates. Org. Lett. 14, 2138–2141 (2012).
Erős, G., Kushida, Y. & Bode, J. W. A reagent for the one-step preparation of potassium acyltrifluoroborates (KATs) from aryl and heteroaryl halides. Angew. Chem. Int. Ed. 126, 7734–7737 (2014).
Ju, L., Bode, J. W., Toma, T. & Fukuyama, T. Amide formation by decarboxylative condensation of hydroxylamines and α-ketoacids: N-[(1S)-1 phenylethyl]-benzeneacetamide. Org. Synth. 87, 218–225 (2010).
Narumi, T. & Bode, J. W. α,α-Dichloroisoxazolidinones for the synthesis and chemoselective peptide ligation of α-peptide α-ketoacids. Heterocycles 82, 1515–1525 (2011).
Juarez-Garcia, M. E., Yu, S. Y. & Bode, J. W. Asymmetric synthesis of enantiopure isoxazolidinone monomers for the synthesis of β3-oligopeptides by chemoselective amide ligation. Tetrahedron 66, 4841–4853 (2010).
Frederickson, M., Grigg, R., Thornton-Pett, M. & Redpath, J. Palladium(II) catalysed oxime–metallo–nitrone–isoxazolidine cascade reactions of α-imino aldoximes. Tetrahedron Lett. 38, 7777–7780 (1997).
Ogunkoya, A. O., Pattabiraman, V. R. & Bode, J. W. Sequential α-ketoacid-hydroxylamine (KAHA) ligations: synthesis of C-terminal variants of the modifier protein UFM1. Angew. Chem. Int. Ed. 51, 9693–9697 (2012).
Venanzi, M. & Kimura, S. Special issue: peptide materials. Polym. J. 45, 467 (2013).
Wennemers, H. Asymmetric catalysis with peptides. Chem. Commun. 47, 12036–12041 (2011).
Taliani M. et al. A continuous assay of hepatitis C virus protease based on resonance energy transfer depsipeptide substrates. Anal. Biochem. 240, 60–67 (1996).
Evans, B. S., Chen, Y. Q., Metcalf, W. W., Zhao, H. M. & Kelleher, N. L. Directed evolution of the nonribosomal peptide synthetase AdmK generates new andrimid derivatives in vivo. Chem. Biol. 18, 601–607 (2011).
Jin, M., Fischbach, M. A. & Clardy, J. A biosynthetic gene cluster for the acetyl–CoA carboxylase inhibitor andrimid. J. Am. Chem. Soc. 128, 10660–10661 (2006).
Acknowledgements
This work was supported by Swiss National Science Foundation (200021_131957), ETH Zürich and the David and Lucille Packard Foundation (Fellowship to J.W.B.). We thank D. Hilvert and R. Obexer for helpful discussions, S. Yu, T. Gerfaud and F. Schuler for preliminary experiments, and G. Erős for selected compounds.
Author information
Authors and Affiliations
Contributions
J.W.B. designed the project and wrote the paper with contributions by Y-L.H.; Y-L.H. performed the experiments and wrote the Supplementary Information. Both authors contributed to discussions.
Corresponding author
Ethics declarations
Competing interests
ETH Zürich has filed a patent application on technology related to the processes described in this article. Both authors are listed as inventors on the patent application.
Supplementary information
Supplementary information
Supplementary information (PDF 5790 kb)
Rights and permissions
About this article
Cite this article
Huang, YL., Bode, J. Synthetic fermentation of bioactive non-ribosomal peptides without organisms, enzymes or reagents. Nature Chem 6, 877–884 (2014). https://doi.org/10.1038/nchem.2048
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/nchem.2048
This article is cited by
-
Streamlining bioactive molecular discovery through integration and automation
Nature Reviews Chemistry (2018)
-
Combichem all over again
Nature Chemistry (2014)
-
Minimalist synthesis
Nature Chemical Biology (2014)